A phase 1 trial of a potent and selective VEGF receptor inhibitor, apatinib, in patients with advanced solid tumors

Authors :: Rachel Kingsford
Sung-Chul Kim
Joan Collett
Glynn Weldon Gilcrease
John R. Weis
Cynthia Davidson
Yoon-Koo Kang
Nicole Orgain
Baek-Yeol Ryoo
Sunil Sharma
Hee-Won Yoo
Min-Hee Ryu
Sook Ryun Park
Source :: Journal of Clinical Oncology. 33:2525-2525
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: 2525 Background: VEGF-mediated signaling pathways are critical to tumor growth. Apatinib mesylate is a novel, oral angiogenesis inhibitor that potently and selectively inhibits vascular endothelial...

Subjects :: Cancer Research
biology
business.industry
Mesylate
VEGF receptors
Pharmacology
Angiogenesis inhibitor
chemistry.chemical_compound
Oncology
chemistry
biology.protein
Medicine
In patient
Apatinib
Tumor growth
Signal transduction
business

Full Text Access

Tools